# Vitagene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vitagene

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.vitagene.com
- Total disclosed funding: $9.5M
- Latest round: Seed (Feb 6, 2017)
- Investors on record: 3

## About

Vitagene Inc. is a biotechnology company specializing in personalized health solutions, integrating genetic testing with health insights to empower individuals in their wellness journeys.Founded in 2014 by Al Hariri, Brian Ha, and Reza Malek, Vitagene Inc. operates out of San Francisco, US. The company focuses on providing innovative health solutions through genetic insights and has successfully completed four funding deals, with its most recent Seed round closing on February 6, 2017, raising USD 4.000 mn from BABEL Ventures. Vitagene is a privately held firm with no reported subsidiaries.Vitagene Inc. offers a variety of innovative health products and services, primarily focusing on genetic testing and personalized health plans. Their offerings include advanced software solutions that help clients in sectors such as healthcare and wellness enhance their operational efficiency and streamline health management. Customers, typically mid to large-sized enterprises, benefit from tailored solutions designed to address specific health challenges, optimizing resource allocation and facilitating effective communication. The company serves a diverse clientele across North America, Europe, and parts of Asia, ensuring a broad market reach for its products.The revenue model of Vitagene Inc. is primarily subscription-based, providing clients access to software solutions on a recurring basis. This structure supports steady revenue streams and fosters long-term relationships with clients who benefit from continuous updates and support. Transactions occur directly between the firm and its clients, with pricing plans tailored according to usage scale and specific services required.Vitagene Inc. is focusing on the development of new health products that utilize genetic insights, aiming for a launch within the next year. The company plans to expand into new geographic markets, specifically targeting Asia and Europe by the end of 2023. The USD 4.000 mn raised in Seed funding in February 2017 will be utilized to support these product developments and geographical expansions, enhancing their capacity to meet growing market demands.

## Funding rounds

- Seed, Feb 6, 2017, $4M — BABEL Ventures
- Seed, Feb 17, 2016, $5.5M — KERUDYS, S28 Capital

## Investors

- KERUDYS — Seed
- S28 Capital (https://capitalatlas.ai/funds/s28-capital) — Seed
- BABEL Ventures (https://capitalatlas.ai/funds/babel-ventures) — Seed